Mast Therapeutics

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Mast Therapeutics sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials none currently recruiting 7 completed early-phase tilt top decile by trial count

Mast Therapeutics: 9 sponsored US clinical trials, none currently recruiting.

Mast Therapeutics sponsors 9 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 7 completed. 2 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Colon Cancer, with 1 trials.

Top-decile sponsor footprint

Mast Therapeutics ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Indexed trials (enrollment closed)

9 total, page 1 of 1

COMPLETED Phase 1

Study of the Effect of Renal Impairment on the Pharmacokinetics of Vepoloxamer

NCT02646358
TERMINATED Phase 2

Evaluation of Vepoloxamer in Chronic Heart Failure

NCT02596477
COMPLETED Phase 3

Evaluation of Repeat Administration of Purified Poloxamer 188

NCT02449616
TERMINATED Phase 2

Evaluation of MST-188 in Acute Lower Limb Ischemia

NCT02093468
COMPLETED Phase 3

Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC)

NCT01737814
COMPLETED Phase 1

ANX-188 Thorough QT/QTc Study in Healthy Volunteers

NCT01790087
COMPLETED Phase 1

A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer

NCT00664170
COMPLETED Phase 1

A Clinical Trial of CoFactor Formulations and Leucovorin Administered Intravenously in Healthy, Adult Subjects.

NCT00663481
COMPLETED Phase 2

Clinical Trial in Patients With Metastatic Colorectal Cancer

NCT00081627

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 3
Phase 3 2

Therapeutic Areas

Colon Cancer 1
Advanced Cancer 1
Rectal Cancer 1
Healthy Adults 1
Healthy 1

How the Mast Therapeutics early-phase archive is shaped

9 indexed studies, none listed as recruiting (0% open); 7 completed (78%).

Phase mix: 2 late (III/IV) vs 7 early (I/II) (early-phase heavy).

Top condition: Colon Cancer (1 trial), 4 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Mast Therapeutics: archived-pipeline peers nationwide

Peers matched on 9 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Mast Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40%50% Total trials Recruiting share Mast Therapeutics4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi company10xBio22nd Century Group23andMe3-C Institute for Social Development
Mast Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Mast Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Mast Therapeutics page

9 registered trials is a research-attention snapshot, not an endorsement of Mast Therapeutics or any single study.

  • None of Mast Therapeutics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Colon Cancer is the condition Mast Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Colon Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Mast Therapeutics pipeline card: 9 registered trials from official public datasets.Report a data error.